Jennifer L. Good - 19 Feb 2026 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Reporting relationship: President & CEO, Director
Issuer ticker: TRVI
Reported as of: 19 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Feb 2026, 16:16:12 UTC
Prior SEC filing: 26 Jun 2025
Next SEC filing: 25 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Galletta, attorney-in-fact

Key filing fact

Jennifer L. Good filed Form 4 for Trevi Therapeutics, Inc. (TRVI) on 20 Feb 2026.

Key facts

This page summarizes Jennifer L. Good's Form 4 filing for Trevi Therapeutics, Inc. (TRVI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Feb 2026, 16:16.

Change

Previous filing in this sequence was filed on 26 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001229245 Primary reporting owner

GOOD JENNIFER L

Relationship: President & CEO, Director
Address: C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN
Signature: /s/ Christopher Galletta, attorney-in-fact
Signature date: 20 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRVI transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +675,000
Change %
Price: $0.000000
Shares after: 675,000
Date: 19 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 675,000
Exercise price: $10.56
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on February 19, 2026. The 675,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer.